These findings demonstrate that micromolar concentrations of cysteamine treatment specifically inhibit MMP activity and TGM2 expression, subsequently decreasing MMP2, MMP9, and MMP14 protein levels in GBM cells. The gene discussed is MMP2; the disease is glioblastoma.